MP38: Prostate Cancer: Localized: Active Surveillance

Poster Session Moderator(s)

• 

  Ahmed Aly, MD

  Clinical Fellow
• 

  Peter Carroll, MD, MPH (he/him/his)

  Professor
  University Of California, San Francisco

Podium Session Moderator(s)

• 

  Kelly Stratton, MD

  Associate Professor
  Department of Urology, Stephenson Cancer Center, University of Oklahoma

Presentations:

• 1:00 PM – 3:00 PM CST

  MP38-01: Patient-level validation of life expectancy cutoffs for triage of aggressive treatment by tumor risk using targeted crowdsourcing
  

  Poster Presenter: John M. Masterson, MD – Cedars-Sinai Urology
• 1:00 PM – 3:00 PM CST

  MP38-02: The Impact of Genomic Biomarkers on a Validated Clinical Risk Prediction Model for Upgrading/Upstaging among Men with Low-risk Prostate Cancer
  

  Poster Presenter: Avery Braun
• 1:00 PM – 3:00 PM CST

  MP38-03: Does Prostate Cancer Family History Have an Impact on Active Surveillance Adherence in Men with Low- or Favourable Intermediate Risk Disease?
  

  Poster Presenter: Riccardo Leni
• 1:00 PM – 3:00 PM CST

  MP38-04: Baseline Prostate Health Index Risk Category and Risk Category Changes During Active Surveillance Predict Grade Reclassification
  

  Poster Presenter: Claire M. De La Calle, MD – Johns Hopkins Univeristy
• 1:00 PM – 3:00 PM CST

  MP38-05: Outcomes of Grade Group 2 and 3 Prostate Cancer on Initial versus Confirmatory Biopsy: Implications for Active Surveillance
  

  Poster Presenter: Marlon L. Perera, MBBS PhD Fulbright – Austin Health
• 1:00 PM – 3:00 PM CST

  MP38-06: Impact of Three Measures of Inherited Prostate Cancer Risk on Upgrading During Active Surveillance for Grade Group 1 Prostate Cancer
  

  Poster Presenter: Claire M. De La Calle, MD – Johns Hopkins Univeristy
• 1:00 PM – 3:00 PM CST

  MP38-07: Upgrading on Per Protocol vs For Cause Surveillance Prostate Biopsies: An Opportunity to Decreasing the Burden of Active Surveillance
  

  Poster Presenter: Michael Wang
• 1:00 PM – 3:00 PM CST

  MP38-08: Is a confirmatory prostate biopsy before entry into an active surveillance protocol still necessary in the era of prostate cancer diagnosis with MRI-guided biopsy?
  

  Poster Presenter: Omri Schwarztuch Gildor
• 1:00 PM – 3:00 PM CST

  MP38-09: Tracking MRI-Invisible Lesions During Active Surveillance
  

  Poster Presenter: Daniel Nemirovsky
• 1:00 PM – 3:00 PM CST

  MP38-10: Multi-institutional validation of the PRECISE criteria on prostate MRI during active surveillance
  

  Poster Presenter: Francesco Giganti, MD PhD (he/him/his)
• 1:00 PM – 3:00 PM CST

  MP38-11: Is There an Impact of the Center Performing Baseline Multiparametric MRI on Active Surveillance Outcomes in Prostate Cancer Patients?
  

  Poster Presenter: Riccardo Leni
• 1:00 PM – 3:00 PM CST

  MP38-12: Persistent Need for Systematic Biopsy for Men on Active Surveillance for early-stage Prostate Cancer
  

  Poster Presenter: Mary Olubukola Fakunle, MD, BS (she/her/hers) – UCSF Urology
• 1:00 PM – 3:00 PM CST

  MP38-13: Has Active Surveillance of Prostate Cancer become safer? Lessons learned from a global clinical registry: Movember GAP3 consortium
  

  Poster Presenter: Paul Doan
• 1:00 PM – 3:00 PM CST

  MP38-14: United States Institutional Variation in the Use of Active Surveillance for Low-risk Prostate Cancer
  

  Poster Presenter: Shu Wang, MD – University of Maryland School of Medicine
• 1:00 PM – 3:00 PM CST

  MP38-15: Discontinuation of Active Surveillance Without Risk Reclassification Prior to Treatment
  

  Poster Presenter: Mark Pressprich, MD, BS
• 1:00 PM – 3:00 PM CST

  MP38-16: Does Testosterone replacement therapy increase the risk of conversion to treatment in patients with prostate cancer on active surveillance?
  

  Poster Presenter: Jorge A. Daza, MD (he/him/his)
• 1:00 PM – 3:00 PM CST

  MP38-17: Prostate cancer grade migration and facility-level treatment trends for low grade disease
  

  Poster Presenter: Ashwin Ramaswamy, MD, MPP (he/him/his) – New York Presbyterian - Cornell
• 1:00 PM – 3:00 PM CST

  MP38-18: Incorporating the PRECISE Recommendations to Evaluate Progression in Men on Active Surveillance for Low-grade Prostate Cancer: Which Patients with Low PRECISE Score Need a Confirmatory Biopsy?
  

  Poster Presenter: Riccardo Leni
• 1:00 PM – 3:00 PM CST

  MP38-19: Focal Therapy Candidacy: An Evaluation of Initial and Continued Eligibility for Focal Therapy in an Active Surveillance Cohort
  

  Poster Presenter: Alexander P. Kenigsberg
• 1:00 PM – 3:00 PM CST

  MP38-20: MRI-guided Active Surveillance without annual re-biopsy in patients with ISUP 1 and 2 prostate cancer – The prospective PROMM-AS Study
  

  Poster Presenter: Jan Philipp Radtke, MD (he/him/his) – Urological Dept. of Heidelberg University Hospital